News - Gastro-intestinals


Current filters:


Popular Filters

50 to 74 of 187 results

Takeda's vedolizumab shows efficacy in colitis and Crohn's disease


A new investigational antibody - vedolizumab - from Japan's largest drugmaker, Takeda Pharmaceuticals…

Gastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Astellas gains marketing approval for Irribow


Japanese drug major Astellas Pharma (TYO: 4503) has gained marketing approval in Japan for Irribow (ramosetron…

Asia-PacificAstellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceutical

Nektar hedges bets on deal with AstraZeneca


Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

IQWiG finds no added benefit proven for Constella in IBS


In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AlmirallConstellaEuropeGastro-intestinalsIronwood PharmaceuticalsPharmaceuticalPricingRegulation

New treatment offers hope for short-bowel syndrome patients


A new drug, teduglutide, offers significant relief for patients with short-bowel syndrome intestinal…

Gastro-intestinalsGattexNPS PharmaceuticalsPharmaceuticalResearchteduglutide

Impax Labs confirms patent challenge to Pfizer/UCB's Toviaz


US specialty drugmaker Impax Laboratories (Nasdaq: IPXL) yesterday confirmed that it has initiated a…

Gastro-intestinalsGenericsImpax LaboratoriesNorth AmericaPatentsPfizerToviazUCB

$10 million milestone for Sucampo, as Takeda starts US selling of Amitiza for OIC


USA-based Sucampo Pharmaceuticals (Nasdaq: SCMP) says that it has received a $10 million milestone payment…

AmitizaFinancialGastro-intestinalsMarkets & MarketingNorth AmericaPharmaceuticalSucampoTakeda Pharmaceuticals

Takeda files BLA for vedolizumab for Crohn's and ulcerative colitis in USA


The US subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has submitted a Biologics…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

First approved new class of IBS-C therapy, Constella, now available in Europe


Spain's largest drugmaker Almirall (ALM: MC) and US partner Ironwood Pharmaceuticals, (Nasdaq: IRWD)…

AlmirallConstellaEuropeGastro-intestinalsIronwood PharmaceuticalsMarkets & MarketingPharmaceuticalRegulation

Second Genome in deal with Janssen on microbiome drug discovery in ulcerative colitis


Second Genome has entered into an agreement with Janssen Biotech, a subsidiary of US health care giant…

Gastro-intestinalsJanssenJohnson & JohnsonLicensingPharmaceuticalResearchSecond Genome

GW Pharma posts six-month results; progresses cannabinoid pipeline including into diabetes and UC


UK biopharma company GW Pharmaceuticals (AIM: GWP), which is developing and commercializing novel therapeutics…

DiabetesFinancialGastro-intestinalsGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

Helsinn and Zealand to advance elsiglutide for chemotherapy-induced diarrhea prevention


Privately-held Swiss pharmaceutical group Helsinn and its partner, Denmark-based Zealand Pharma A/S (Nasdaq:…

elsiglutideGastro-intestinalsHelsinnOncologyPharmaceuticalResearchZealand Pharma

US FDA approves Janssen's Simponi to treat ulcerative colitis


The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

AbbVie and Alvine link up on investigational oral therapy for celiac disease


US drugmaker AbbVie (NYSE: ABBV) and privately-held Alvine Pharmaceuticals, a leader in celiac disease…

AbbVieALV003Alvine PharmaceuticalsGastro-intestinalsLicensingPharmaceuticalResearch

Shire prevails in US Lialda patent dispute with Watson


Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsPharmaceuticalShireWatson Pharmaceuticals

Vedolizumab has potential to offer improvement over infliximab in UC


Surveyed US and EU5 gastroenterologists agree that new moderate to severe ulcerative colitis (UC) therapies…

EuropeGastro-intestinalsinfliximabJanssenMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Positive Ph IIb results for SALVAT's tarafenacin in overactive bladder


Spanish drugmaker Laboratorios SALVAT and its South Koran partner Kwang Dong Pharmaceutical have released…

Gastro-intestinalsKwang Dong PharmaceuticalLaboratorios SALVATLicensingPharmaceuticalResearchtarafenacin

FDA approves Eisai's Aciphex Sprinkle for GERD in children; Inovelon OKed in Japan


Japanese drug major Eisai (TYO: 4523) says that the US Food and Drug Administration has approved Aciphex…

AciphexAsia-PacificEisaiGastro-intestinalsInovelonNeurologicalNorth AmericaPharmaceuticalRegulation

Zeria and Astellas' Acofide approved in Japan for functional dyspepsia


Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the marketing of Acofide (acotiamide…

AcofideAsia-PacificAstellas PharmaGastro-intestinalsPharmaceuticalRegulationZeria Pharmaceuticals

50 to 74 of 187 results

Back to top